Patient demographics and disease characteristics at baseline (prior to commencement of TNFi)
| Demographics | % | |
| Cohort size | 43 | – |
| Age at study entry (SD) | 38.9 (11.6) | – |
| Female gender | 27 | 62.8 |
| Ethnicity | ||
| Caucasian | 42 | 97.7 |
| Asian | 1 | 2.3 |
| Afro-Caribbean | 1 | 2.3 |
| Bilateral disease | 31 | 72.3 |
| Median duration of disease prior to biologic therapy, years (IQR) | 3.0 (7.0) | |
| Anatomical classification of ocular disease | ||
| Anterior uveitis | 3 | 7 |
| Intermediate uveitis | 8 | 18.6 |
| Panuveitis | 13 | 30.2 |
| Posterior uveitis | 15 | 34.9 |
| Scleritis | 4 | 9.3 |
| Aetiology | ||
| Idiopathic | 19 | 44.2 |
| Systemic vasculitis | 1 | 2.3 |
| Ankylosing spondylitis | 1 | 2.3 |
| Behcet’s | 15 | 34.8 |
| Juvenile idiopathic arthritis | 2 | 4.6 |
| Juvenile sarcoidosis | 1 | 2.3 |
| Psoriatic arthropathy | 2 | 4.6 |
| Sarcoidosis | 1 | 2.3 |
| Undifferentiated arthritis | 1 | 2.3 |
| Visual acuity logMAR score | ||
| ≤0 | 14 | 33 |
| >0.1, ≤0.3 | 18 | 41.8 |
| >0.3, ≤1 | 9 | 20.9 |
| >1 | 2 | 4.6 |
| Clinical disease activity | ||
| Anterior chamber inflammation ≥1+ | 7 | 16.3 |
| Cystoid macular oedema (active inflammation) | 9* | 20.9 |
| Vitreous haze score ≥1 | 5 | 11.6 |
| Retinal vasculitis | 23 | 53.5 |
| Choroidal inflammation | 2 | 4.6 |
| Missing data | 0 | – |
| Comorbidities/Complications | ||
| Glaucoma | 6 | 14.0 |
| Ocular hypertension | 2 | 4.6 |
| Epiretinal membrane | 14 | 32.6 |
| Cataract | 12 | 27.9 |
| Retinal ischaemia within the macula | 8 | 18.6 |
| Retinal ischaemia within peripheral retina | 12 | 27.9 |
*Missing data for one patient.
TNFi, tumour necrosis factor-alpha inhibitor; logMAR, logarithm of the minimum angle of resolution.